Mental Health Technologies Co. Ltd. (9218) AI Stock Analysis

• Market Cap: ¥7.92B
• Dividend Yield: N/A
• Average Volume (3M): 54.69K
• Price to Earnings (P/E): 30.9
• Beta (1Y): 0.77
• Revenue Growth: 41.16%
• EPS Growth: 2750.91%
• Country: JP
• Employees: 137
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.48
• Shares Outstanding: 10,447,300
• 10 Day Avg. Volume: 35,240
• 30 Day Avg. Volume: 54,690
• PEG Ratio: -0.04
• Price to Book (P/B): 5.43
• Price to Sales (P/S): 1.32
• P/FCF Ratio: 15.25
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 61.6
• Revenue Forecast (FY): ¥7.80B

• Rating: 52 Neutral
• Price Target: ¥763.00 ▼(-6.95% Downside)
• Action: Downgraded Date: 02/18/26
• Date: Action: Downgraded 02/18/26

The score is primarily supported by improving 2025 fundamentals and cash flow, but is held back by elevated leverage and sharply compressed margins. Technicals are weak with the stock trading below key moving averages and negative MACD, and valuation remains relatively expensive (P/E ~32) with only a modest dividend yield.

Positive Factors

Revenue recovery & return to profitability

The 2025 re-acceleration of revenue and return to profitability indicate the company can scale its offerings and convert demand into earnings. Over 2–6 months this supports operational stability, reduces reliance on external financing, and enhances capacity to reinvest in product and distribution.

Improved cash generation

Stronger operating and free cash flow increases financial flexibility and funds capital allocation without immediate external funding. Durable FCF near net income improves ability to meet debt service and finance growth initiatives, enhancing resilience over the coming months if maintained.

Re-accelerating revenue growth rate

A double-digit reported revenue growth rate signals renewed market traction and product adoption. Sustained top-line momentum supports scale benefits, potential margin recovery, and stronger free cash flow generation, providing a runway for strategic investments over the medium term.

Negative Factors

Elevated leverage

A materially higher debt load increases fixed obligations and refinancing risk, reducing strategic flexibility. With leverage markedly up versus prior years, adverse swings in margins or cash flow could force costly refinancing, constrain R&D/capex, or pressure liquidity over the next several quarters.

Structural margin compression

Severe gross margin decline and slim net margins reduce the company’s buffer against cost inflation or pricing pressure. Sustained lower margins limit reinvestment capacity and make profitability highly sensitive to execution, increasing operational risk over the medium term.

Inconsistent cash conversion history

Historical volatility in operating and free cash flow implies earnings quality and convertibility concerns. If cash conversion reverts, debt servicing and funding plans could be stressed; recent FCF gains may not be durable without structural operating improvements.

Mental Health Technologies Co. Ltd. Business Overview & Revenue Model

Company Description

Mental Health Technologies Co.,Ltd. engages in mental health solutions, physician career support, and digital marketing businesses in Japan. It is also involved in industrial physician cloud business. The company was incorporated in 2011 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Mental Health Technologies Co. Ltd. generates revenue primarily through subscription-based models for its software applications and teletherapy services. Users pay monthly or annual fees to access premium features, including personalized therapy plans, AI-driven assessments, and additional resources. The company also earns revenue from partnerships with healthcare providers and institutions, which utilize its technology to enhance their mental health services. Furthermore, grant funding and collaborations with research organizations contribute to its financial growth, allowing the company to innovate and expand its offerings in the mental health space.

Mental Health Technologies Co. Ltd. Financial Statement Overview

Summary

Income statement and cash flow show a 2025 recovery (re-accelerating revenue growth, return to profitability, and stronger operating/free cash flow). However, the balance sheet is a major constraint: leverage is elevated (debt-to-equity ~1.67 in 2025 vs. ~0.28–0.30 in 2022–2023), and margins have structurally compressed (gross margin down to ~32% in 2025 with a thin ~4% net margin).

Income Statement

Revenue momentum improved materially in 2025 (up ~9% vs. 2024) after modest growth in 2024, and the company returned to profitability in 2025 following a small loss in 2024. However, profitability has structurally stepped down versus 2022–2023: gross margin has compressed meaningfully (mid-60% in 2022 to ~32% in 2025), and net margin is thin in 2025 (~4%), indicating less room for execution error despite positive earnings.

Balance Sheet

Leverage has increased sharply over time: debt-to-equity moved from ~0.28–0.30 in 2022–2023 to ~2.0 in 2024 and ~1.67 in 2025, reflecting a heavier reliance on debt funding. While equity has grown since 2023, the current capital structure still looks debt-heavy for the business profile, which can constrain flexibility if margins or growth soften.

Cash Flow

Cash generation is a key positive: operating cash flow and free cash flow improved strongly in 2025 versus 2024, and free cash flow remains robust relative to earnings (free cash flow is close to net income in 2025). That said, cash conversion has been uneven historically (including negative operating and free cash flow in 2020 and weaker coverage in 2024), so consistency remains an area to monitor.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.88B	6.44B	5.13B	2.61B	2.29B	1.45B
Gross Profit	1.94B	2.03B	1.84B	1.45B	1.43B	769.72M
EBITDA	639.20M	661.94M	224.92M	559.90M	427.19M	162.13M
Net Income	329.12M	254.90M	-29.78M	441.37M	265.12M	161.83M
Balance Sheet
Total Assets	4.66B	5.37B	4.63B	1.73B	1.30B	663.62M
Cash, Cash Equivalents and Short-Term Investments	909.50M	1.49B	1.12B	913.71M	659.51M	423.50M
Total Debt	2.38B	2.62B	2.57B	332.49M	183.78M	188.52M
Total Liabilities	3.20B	3.80B	3.33B	618.32M	640.75M	416.20M
Stockholders Equity	1.46B	1.57B	1.29B	1.12B	655.37M	247.42M
Cash Flow
Free Cash Flow	0.00	558.09M	199.15M	111.83M	325.17M	181.38M
Operating Cash Flow	0.00	631.99M	270.51M	177.54M	377.49M	202.14M
Investing Cash Flow	0.00	-324.30M	-2.15B	-90.61M	-260.33M	-20.79M
Financing Cash Flow	0.00	67.82M	2.08B	167.28M	118.85M	53.33M

Mental Health Technologies Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 820.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9218, the sentiment is Negative. The current price of 820 is above the 20-day moving average (MA) of 767.45, above the 50-day MA of 799.54, and above the 200-day MA of 768.53, indicating a bearish trend. The MACD of -17.66 indicates Positive momentum. The RSI at 44.35 is Neutral, neither overbought nor oversold. The STOCH value of 49.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9218.

Mental Health Technologies Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4320	77 Outperform	¥22.21B	12.35	―	4.99%	8.77%	1078.88%
4263	56 Neutral	¥18.81B	-72.81	―	―	39.30%	32.06%
6034	56 Neutral	¥3.61B	65.83	―	―	1.51%	-13.66%
9218	52 Neutral	¥7.92B	30.86	―	―	41.16%	2750.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2934	42 Neutral	¥7.07B	-66.36	―	―	11.40%	―
3628	40 Underperform	¥5.89B	-2.57	―	―	-4.07%	-88.89%